XORTX Announces New Clinical Advisory Board Member
March 27 2024 - 5:00AM
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:
XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a
biopharmaceutical company focused on developing innovative
therapies to treat autosomal dominant polycystic kidney disease
(“ADPKD”), is pleased to announce that Dr. Ronald Perrone has
joined the Company’s Clinical Advisory Board.
Dr. Allen Davidoff stated, “We are excited that
Dr. Ron Perrone has agreed to join XORTX’s Clinical Advisory Board.
Dr. Perrone brings substantial medical and professional experience
as a thought leader, combined with clinical experience treating
patients with ADPKD and kidney disease. We are privileged to have
Dr. Perrone join our esteemed Clinical Advisory Board alongside
current members, Dr. Petter Bjornstad, Dr. Richard Johnson, Dr.
Federico Maese, Dr. Anjay Rostogi and Dr. Charles Edelstein. We
look forward to the valuable contributions that he can bring to our
advanced clinical program and specifically the XRX-OXY-201
registration trial designed to slow progression of ADPKD.”
Dr. Ronald Perrone, MD is Professor of Medicine
at Tufts University School of Medicine in Boston, Massachusetts.
Dr. Perrone is board certified in Nephrology. He did his Internal
Medicine residency at Grady Memorial Hospital in Atlanta and
Nephrology fellowship at Boston University Medical Center. Ron’s
research involves clinical investigations focused on kidney disease
with a special emphasis on polycystic kidney disease (“PKD”). He is
heavily involved in clinical research in ADPKD clinical trials and
works with regulatory agencies such as the US Food and Drug
Administration (“FDA”) to contribute to the development of database
assessment tools to validate total kidney volume as a biomarker for
PKD progression. Dr. Perrone’s focus on translational clinical
trial interventions in ADPKD includes trials for Sanofi, Reata,
Palladio Biosciences, HALT-PKD, the TAME PKD Metformin trial, TEMPO
and REPRISE trials for Tolvaptan. Ron also initiated a PKD Database
Consortium in 2007 which led to the creation of the PKD Outcomes
Consortium in 2009. The PKD Outcomes Consortium, comprising
contributors from academia, the pharmaceutical industry, National
Institute of Health (“NIH”), FDA, the Clinical Data Interchange
Standards Consortium (“CDISC”), and the Critical Path Institute
(C-Path), is creating the groundwork for validation of for
biomarkers and clinical trial and regulatory endpoints in ADPKD.
This work is ongoing and involves frequent interactions with the
FDA and the European Medicines Agency.
A full list of Dr. Perrone’s publications can be
found at: https://pubmed.ncbi.nlm.nih.gov/?term=perrone+rd.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development: 1) our lead, XRx-008
program for ADPKD; and 2) our secondary program in XRx-101 for
acute kidney and other acute organ injury associated with
Coronavirus / COVID-19 infection. In addition, XRx-225 is a
pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX
is working to advance its clinical development stage products that
target aberrant purine metabolism and xanthine oxidase to decrease
or inhibit production of uric acid. At XORTX, we are dedicated to
developing medications to improve the quality of life and future
health of patients. Additional information on XORTX is available at
www.xortx.com.
For more information, please contact: |
|
Allen
Davidoff, CEO |
|
Nick
Rigopulos, Director of Communications |
adavidoff@xortx.com or +1 403 455 7727 |
|
nick@alpineequityadv.com or +1 617 901 0785 |
|
|
|
Kim Golodetz, LHA Investor Relations |
|
|
kgolodetz@lhai.com or 1 212 838 3777 |
|
|
|
|
|
Neither the TSX Venture Exchange nor Nasdaq has
approved or disapproved the contents of this news release. No stock
exchange, securities commission or other regulatory authority has
approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied
forward-looking statements pursuant to U.S. Federal securities
laws. These forward-looking statements and their implications are
based on the current expectations of the management of XORTX only,
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements. Except as otherwise required by
law, XORTX undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting XORTX is contained under the heading “Risk
Factors” in XORTX’s Registration Statement on Form F-1 filed with
the SEC, which is available on the SEC's website, www.sec.gov
(including any documents forming a part thereof or incorporated by
reference therein), as well as in our reports, public disclosure
documents and other filings with the securities commissions and
other regulatory bodies in Canada, which are available on
www.sedarplus.ca.
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024